Bio Green Med Solution (BGMS) Cash from Financing Activities (2010 - 2026)
Bio Green Med Solution (BGMS) posted quarterly Cash from Financing Activities of $105000.0 for Q1 2026, down 97.12% year-over-year from $3.6 million in Q1 2025, and up 140.54% quarter-over-quarter from -$259000.0 in Q4 2025.
Powered by 
Analysis
Bio Green Med Solution (BGMS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Bio Green Med Solution (BGMS) has reported Cash from Financing Activities for 17 consecutive years, with $105000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 97.12% year-over-year to $105000.0; the TTM figure through Mar 2026 stood at $1.7 million (down 85.08% YoY), while the FY2025 annual figure was $5.3 million, down 32.7% from the prior year.
- Cash from Financing Activities climbed to $105000.0 in Q1 2026 per BGMS's latest filing, from -$259000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $6.3 million in Q2 2024 and bottomed at -$259000.0 in Q4 2025.
- Historically, Cash from Financing Activities has averaged $1.0 million across 5 years, with a median of $42000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 12431.37% — and 2025, when it plunged 200.0%.
- Bio Green Med Solution's Cash from Financing Activities stood at $42000.0 in 2022, then jumped by 2278.57% to $999000.0 in 2023, then surged by 61.46% to $1.6 million in 2024, then tumbled by 116.06% to -$259000.0 in 2025, then jumped by 140.54% to $105000.0 in 2026.
- Business Quant data shows BGMS's Cash from Financing Activities at $105000.0 in Q1 2026, -$259000.0 in Q4 2025, and -$3000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.25 Bn | 133.40 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.50 Bn | 78.51 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.96 Bn | 59.78 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.57 Bn | 52.43 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.65 Bn | 44.65 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.37 Bn | 35.27 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.40 Bn | 32.09 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.60 Bn | 26.44 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Bio Green Med Solution | 4.87 Mn | 1.08 Mn | 79,000.00 | 773,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 773,000.00 |
| Mar 31, 2026 | 105,000.00 |
| Dec 31, 2025 | -259,000.00 |
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | 1.88 Mn |
| Mar 31, 2025 | 3.65 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | 6.29 Mn |
| Mar 31, 2024 | -79,000.00 |
| Dec 31, 2023 | 999,000.00 |
| Sep 30, 2023 | -50,000.00 |
| Jun 30, 2023 | -51,000.00 |
| Mar 31, 2023 | -50,000.00 |
| Dec 31, 2022 | 42,000.00 |
| Sep 30, 2022 | 1.53 Mn |
| Jun 30, 2022 | 1.47 Mn |
| Mar 31, 2022 | -50,000.00 |
| Dec 31, 2021 | 887,000.00 |
| Sep 30, 2021 | 2.90 Mn |